The SAKURA study is a Phase III, multinational, double-masked trial investigating the safety and efficacy of DE-109 for the treatment of non-infectious uveitis of the posterior segment. DE-109 is a proprietary formulation of sirolimus that is an anti-inflammatory agent. If you have been diagnosed with uveitis of the posterior segment or if you have questions regarding this study, please contact Kate Cernok, PhD at kcernok@santeninc.com.
SAKURA Phase III Study
The SAKURA study is a Phase III, multinational, double-masked trial investigating the safety and efficacy of DE-109 for the treatment of non-infectious uveitis of the posterior segment. DE-109 is a proprietary formulation of sirolimus that is an anti-inflammatory agent. If you have been diagnosed with uveitis of the posterior segment or if you have questionsLearn More
November 13, 2015
Categories
Recent Posts
- FSR, Walgreens, & Cedars-Sinai Provide Free N95 Masks to Protect LA Wildfire Survivors
- Honoring a Mother’s Legacy: Molly Flick’s Fight Against Sarcoidosis
- When exposed to wildfires and during the clean up take the following precautions to protect your health
- Celebrating FSR’s 25 Years of Innovation, Empowerment, and Progress: Shaping the Future Together!
- FSR Awards $300k in Grant Funding to Improve Diagnosis and Treatment of Sarcoidosis